Please login to the form below
Xeljanz
This page shows the latest Xeljanz news and features for those working in and with pharma, biotech and healthcare.
FDA panel undermines Lilly and Incyte’s baricitinib hopes
But analysts think the drug faces an uphill battle now to win market share from Pfizer’s Xeljanz (tofacitinib), the first JAK inhibitor to reach the market for RA in the ... Taking on Xeljanz isn’t the only challenge for baricitinib, however, as it
Latest news
-
AbbVie’s upadacitinib aces phase III trial
The drug is vying to become the third drug in the class after Pfizer’s Xeljanz (tofacitinib) and Eli Lilly’s Olumiant (baricitinib), which was turned down by the FDA at
-
AbbVie reports more solid data for would-be psoriasis blockbuster
Upadacitinib is vying to become the third drug in the class after Pfizer’s Xeljanz (tofacitinib) and Eli Lilly’s Olumiant (baricitinib) as a rheumatoid arthritis treatment, reporting encouraging phase III
-
J&J takes option on Theravance’s JAK drug in $1bn deal
Hedging the bets could be a good move. J&J is entering what is looking to be an increasingly crowded JAK field, with Pfizer’s Xeljanz (tofacitinib) approved since 2012 and
-
AbbVie’s JAK inhibitor upadacitinib clears another phase III trial
The selective JAK1 inhibitor – which is vying to become the third drug in the class after Pfizer’s Xeljanz (tofacitinib) and Eli Lilly’s Olumiant (baricitinib) – met the objective of improving ... Xeljanz is still growing strongly as an oral
-
NICE backs Pfizer’s Xeljanz for RA
NICE backs Pfizer’ s Xeljanz for RA. But UK’s cost-effectiveness watchdog removes two drugs from CDF. ... Pfizer is celebrating a positive recommendation from the National Institute for Health and Care Excellence (NICE) for Xeljanz (tofacitinib
More from news
Approximately 18 fully matching, plus 35 partially matching documents found.
Latest Intelligence
-
Pharma deals during September 2013
antibody (MAb) Actemra and Pfizer's JAK inhibitor Xeljanz.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
Infographic: RA Perceptions
The greatest levels of familiarity and interest were reported for novel small molecules such as Celgene’ s Otezla (apremilast) and Pfizer’ s Xeljanz (tofacitinib), which both offer a new oral alternative ... Of the physicians who were familiar with
-
Brand leaders in RA will lose market share, predict rheumatologists
JAK-inhibitors were the most commonly mentioned class, with Xeljanz the most frequently cited product. ... The EMA’ s refusal to grant a marketing authorisation for Xeljanz was disappointing for Pfizer, however, the drug is said to be performing in
More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.
Featured jobs
- Editor > Senior Editor – Medical Education – London
-
Very competitive with excellent benefits
- Head of Operations/ BUD, Healthcare PR, London – Excellent leade...
-
Excellent Package
-
Account Manager, Healthcare PR
-
£40, 000 – £42, 000 great benefits and bonuses
-
Senior Medical Writer
-
Great salary and benefits
- Senior Account Manager – Med Comms – Kent
-
Salary TBC
-
Senior Medical Writer
-
Great salary and bebefits
- Senior / Principal Regulatory Writer – Home Working - UK or US
-
HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS
- Editor – Medical Education Agency – Bucks
-
Salary TBC
-
Senior Programme Executive
-
Salary TBC
- FREELANCE Account Manager – Creative Healthcare Advertising – Lo...
-
SUPERB DAY RATES AVAILABLE
- Senior Account Manager / Account Director
-
Great salary and bebefits
- FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...
-
EXCELLENT DAY RATES AVAILABLE
- Editorial Team Leader or Scientific Director
-
£50, 000 - £55, 000 benefits
-
Scientific Director
-
Great salary and bebefits
- Senior Medical Writer, Medical Communications, Relocate to Cardi...
-
Excellent Salary
- Account Manager – Med Comms – London
-
Salary TBC
- Principal Medical Writer, Medical Communications, Relocate to Ca...
-
Excellent Salary
Subscribe to our email news alerts
PMHub
3 Monkeys Zeno
3 Monkeys Zeno is the UK arm of Zeno Group, a global integrated communications consultancy. Everything we do is rooted...
Latest intelligence
- Pharma’s isolated islands of innovation
- With service design and technology often failing the patient, why perspective on improving outcomes need to change...
- Uncertainty, austerity and Brexit
- What does it mean for the life science sector?...
- The Holy Grail of HCP Access
- This is the data you need to gain access....
Quick links
Infographics
